Neogenomics Stock News

NeoGenomics, Inc. (NASDAQ:NEO) insider Douglas Matthew Brown sold 33,333 shares of the firms stock in a transaction on Tuesday, November 23rd. The shares were sold at an average price of $37.19, for a total transaction of $1,239,654.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through []

NeoGenomics, Inc. (NASDAQ:NEO) insider Douglas Matthew Brown sold 33,334 shares of the companys stock in a transaction that occurred on Friday, November 26th. The stock was sold at an average price of $36.85, for a total value of $1,228,357.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is []

NeoGenomics, Inc. (NASDAQ:NEO) insider Douglas Matthew Brown sold 33,333 shares of the businesss stock in a transaction dated Tuesday, November 23rd. The stock was sold at an average price of $37.19, for a total value of $1,239,654.27. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. []

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have earned an average recommendation of Buy from the eleven analysts that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month price target among brokerages that []

NeoGenomics with ticker code (NEO) have now 10 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 60 and 45 with a mean TP of 51.7. Given that the stocks previous close was at 37.28 this would indicate that there is a potential upside of 38.7%. The day 50 moving average is 44.06 and the 200 moving average now moves to 45.69. The market capitalisation for the company is $4,633m. Visit the company website at: /> [stock_market_widget type="chart" symbol="NEO" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] NeoGenomics operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains.

NeoGenomics Inc. (NASDAQ:NEO)s traded shares stood at 0.68 million during the last session, with the companys beta value hitting 0.59. At the close of trading, the stocks price was $40.03, to imply an increase of 2.64% or $1.03 in intraday trading. The NEO shares 52-week high remains $61.57, putting it -53.81% down since that peak NeoGenomics Inc. (NASDAQ: NEO) Surged 2.67% In 6 Months Heres What Happens Next Read More »

Thrivent Financial for Lutherans raised its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 0.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 96,405 shares of the medical research companys stock after purchasing an additional 343 shares during the period. Thrivent Financial for Lutherans owned []

Goldman Sachs Group Inc. lowered its position in NeoGenomics, Inc. (NASDAQ:NEO) by 19.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 235,678 shares of the medical research companys stock after selling 57,938 shares during the quarter. Goldman Sachs Group Inc. owned about []

NeoGenomics, Inc.'s (NEO) CEO Mark Mallon on Q3 2021 Results - Earnings Call Transcript

NeoGenomics (NASDAQ:NEO) reported its Q3 earnings results on Thursday, November 4, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Inivata Announces Clinical Collaboration with Princess Margaret Cancer Cente r for the us e of its Liquid Biopsy Assay s

Two clinical studies including interventional RaDaR™ study FT. MYERS, FL / ACCESSWIRE / October 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing servic

FT. MYERS, FL / ACCESSWIRE / October 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plan

Appoints Lead Independent Director Lynn Tetrault as Non-Executive Chair. Douglas VanOort steps-down as Executive Chairman and will retire from the Board of Directors before the end of the year FT.

Guardant Health Inc (NASDAQ: GH) has decided not to pursue a potential acquisition of NeoGenomics Inc (NASDAQ: NEO), Bloomberg reported citing people familiar with the matter. Related:   Guardan